CAR T cells show faster transduction time in multiple myeloma


June 28, 2022

1 minute watch


Source/Disclosures


Source: Healio Interview


Disclosures: Krishnan reports leadership roles at Sutro Biopharma; funding of research at his institution by Janssen; consultant/advisory roles with Bristol Myers Squibb, GlaxoSmithKline and Janssen; speaker bureau roles with Amgen, Bristol Myers Squibb, GlaxoSmithKline and Takeda; and the shareholding of Bristol Myers Squibb.


We have not been able to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

In this video, Amrita KrishnanMD, director of the Judy and Bernard Briskin Center for Multiple Myeloma Research at the City of Hope Cancer Center, discusses major developments in multiple myeloma presented at the ASCO Annual Meeting.

Krishnan highlights new data on chimeric antigen receptor T cells, including indications that CAR T cells have significant growth margin in the multiple myeloma sphere.

“This suggests that we have more room to optimize our CAR-T products in terms of efficacy and time to delivery to the patient,” Krishnan said.

Previous Obituary: Dana M. Lord - Lewiston Sun Journal
Next How safe are Amtrak trains as transportation?